RE:What are the opinions out there...~20% below All-time-highs, Health Canada approvals brought the SP to support $4.60's but recent selloff from highs pushed below that to a bottom of $4.40's. I estimate we could technically see $4.60's or $4.50's but the upside is far greater than these small potential dips would provide. The price targets on this board are abnormally high for any stock but that does not come out of nowhere. These targets are supported by game-changing tech and with these recent approvals, it proves the company has the goods to back up their claims. Now we wait for more regulatory approvals, contracts, and TSX/NASDAQ uplistings (with a change of business). IMO biggest potential is the pharmaceutical which would revolutionize many aspects of healthcare depending on which drug delivery methods work best.
Currently, the company is seeking to apply this drug to skincare in attempt to remedy psoriasis, acne, diabetic foot, the list goes on; then gut treatment for infections, such as VRE and C. Difficile. This is the longest term- yet greatest upside- potential for this company. These are DOZEN $billion markets for each disease that it can find applications for, but if they can prove that the compound does not affect human physiology at all? Obviously a great opportunity for the 'treatment' markets. This would be stunted if it came to light that ill-effects are to be expected from certain delivery methods (such as to the lungs..)
For the moment, focus is PPE and filtration media as a proven 'prevention' aspect of the markets, but in 2022 a 'detection' market is anticipated to be full-steam ahead through software that connects the detector to a device and management system. A prototype of the system is expected to be completed in 2022, at which point a final commercialization strategy will be determined based on the market data. Intent is then to request approval for the rapid test at Health Canada.
One of the other great aspects is a diverse portfolio which, depending on R&D results, is expected to justify another pilot plant application in 2022 for anything among this list:
Corrosion Protection Coatings, Fuel Performance Enhancing Additive, 3D conductive filaments for a variety of applications, graphene quantum dot synthesis and applications, graphene synthesis, upscaling recycled plastics, magnetic filament fabrication...
The diversity suggests this will not be one company in the future, but a spin-off structure resulting in a conglomerate. ZEN itself for 2022 I remain at a price target projected from a 'potential' EPS of $3 for 2022. Something toward $40 or $90 if there is substantial liquidity and news coverage.
One thing is for certain, daytraders and short interest will make sure we get to fair value slower than we anticipate..